Liom
- Company typePrivate
- Founded2021
- HeadquartersPfäffikon, Switzerland
- Headcount51–100
- GTM typeB2C
- OfferingHardware or Manufacturing
Liom firmographics
Firmographics- Name
- Liom
- Legal name
- Liom Health AG
- Website
- https://liom.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Liom industry classification
Industry- Product category
- Wearable Health Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals (334515)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Instruments For Meas & Testing Of Electricity & Elec Signals (3825)
- akta.pro industry
- Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers)Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)Health Monitoring Wearables (ECG, BP, SpO2, CGM-compatible)Consumer Products & Retail/Consumer Electronics & Appliances Retail/Wearables & Personal Tech Retail
Keywords
Where Liom is headquartered
LocationHeadquarters
- HQ city
- Pfäffikon
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Liom business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Revenue model
- Wearable Device Sales: Sale of non-invasive glucose monitoring wearable device to consumers and athletes
- Health Data Subscription Services: Potential recurring revenue from ongoing health monitoring, predictive alerts, meal optimization, and time-in-range analytics services
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Liom product offering
Product offeringCore offering
Liom develops a non-invasive, calibration-free wearable device that monitors glucose and other biomarkers continuously using a proprietary miniaturized Raman spectroscopy platform. The smartwatch-sized wearable analyzes light scattering at the wrist to deliver needle-free glucose readings alongside broader metabolic, fitness, cardiovascular, sleep, and mental wellness metrics, with planned commercial launch in 2028.
Product overview
Liom offers a unified health wearable platform centered on its non-invasive glucose monitoring device. The core product is a Raman spectroscopy-based wearable that provides calibration-free, needle-free glucose measurements integrated with broader health metrics. The platform architecture includes multiple monitoring modules: Metabolic (continuous glucose monitoring with predictive alerts and meal optimization), Fitness (activity tracking and metabolic burn analysis), Cardiovascular (heart rate, variability, respiratory rate), Sleep (quality analysis and stages), and Mental (focus, energy, and stress tracking). Previously operated under the brand name 'Spiden' before rebranding to Liom in July 2024.
Differentiator
Problem solved
Functional benefit
Products and services
- Liom Non-Invasive Glucose Monitoring Wearable A smartwatch-sized wearable device that uses proprietary miniaturized Raman spectroscopy to monitor glucose levels non-invasively through light scattering analysis at the wrist, without needles, skin piercing, or calibration. Designed for health-conscious consumers and athletes, with planned commercial launch in 2028.
Quantifiable outcome
- Continuous glucose monitoring without skin piercing - world first
- +2 more outcomes
Companies that use Liom
Customer profileSegments3 records
Ideal customer profiles2 records
Liom technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
Liom partnerships and signals
Strategic signalScale indicators7 records
Recent moves7 records
Expansion highlights6 records
Liom competitors and assessment
Company assessmentBroad incumbents
- Apple: Reportedly investing heavily in non-invasive glucose monitoring as a future Apple Watch feature. While not yet shipping, Apple represents the most consequential potential entrant: massive R&D budget, established consumer wearable distribution, and brand power could compress Liom's addressable market if launched before 2028.
- Medtronic Diabetes: Global medical device incumbent offering the Guardian CGM system as part of its insulin pump ecosystem. Relevant competitor in glucose monitoring with established payor and clinician channels; less direct overlap with Liom's non-invasive approach but defines the integrated diabetes care landscape.
- Dexcom: Market leader in continuous glucose monitoring with the G6/G7 product lines. Directly competes with Liom in glucose monitoring but uses an invasive under-skin sensor rather than Liom's non-invasive optical approach. As an established, FDA-cleared CGM incumbent, it defines the accuracy and clinical workflow benchmark Liom must meet.
- Abbott Diabetes Care (Freestyle Libre): World's largest CGM franchise with the Freestyle Libre series. Competes directly with Liom in glucose monitoring via a needle-based patch sensor. Abbott's scale, payor relationships, and established brand make it the primary entrenched competitor Liom must displace in the consumer glucose category.
Direct peers
- Know Labs: U.S.-based developer of non-invasive glucose monitoring using radio frequency spectroscopy (BodyTell/KnowU). Direct competitor pursuing a needle-free, calibration-light glucose solution; a relevant technology alternative and competitive threat in the non-invasive CGM space.
- Senseonics (Eversense): Developer of the Eversense implantable CGM with 6-month sensor duration. Directly comparable as a glucose monitoring technology challenger targeting improved user experience over incumbents; though invasive, it represents an alternative approach to Liom's non-invasive wearable.
Emerging players
- Ultrahuman: Consumer wearable (M1 glucose monitor / Ring) company selling continuous glucose monitoring and metabolic insights to health-conscious consumers and athletes — a very close comparable on go-to-market (DTC, athletes, metabolic optimization), although it currently relies on Abbott CGM sensors rather than proprietary non-invasive hardware.
- Movano Health: Public health-tech company developing the Evie Ring and related wearable health monitors, including blood pressure and metabolic signals. Comparable as a smaller wearable health device company pursuing multi-metric monitoring, though currently focused on different biomarkers than Liom.
- Biolinq: Developer of needle-free biosensor patches for continuous metabolic monitoring. Closely comparable to Liom in target market (glucose/metabolic monitoring) and product vision (a small wearable patch), though using electrochemical biosensors rather than optical spectroscopy.
Others
- Levels Health: Subscription-based metabolic health platform built on top of existing CGM sensors, providing insights to consumers. Comparable as a metabolic health subscription business model, but does not develop hardware and currently depends on incumbent CGM devices.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Liom social profiles
Digital presenceLiom compliance and trust
Trust signalCompliance1 record
Liom financial estimates
Financial estimateRevenue estimate
Valuation estimate
Liom leadership team
Management profileNumber of profiles
Profiles6 records
Liom funding detail
Funding detailFunding overview
Funding rounds10 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Liom M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Liom
What does Liom do?
Liom develops a non-invasive, calibration-free wearable device that monitors glucose and other biomarkers continuously using a proprietary miniaturized Raman spectroscopy platform. The smartwatch-sized wearable analyzes light scattering at the wrist to deliver needle-free glucose readings alongside broader metabolic, fitness, cardiovascular, sleep, and mental wellness metrics, with planned commercial launch in 2028.
Is Liom a public or private company?
Liom is a private company. It is classified as venture growth investor backed and is currently operating.
When was Liom founded?
Liom was founded in 2021. It employs 51 to 100 people.
Where is Liom based?
Liom is headquartered in Pfäffikon, Switzerland, in the Europe region.
How does Liom make money?
Two revenue lines are on record. Wearable Device Sales are the primary driver. The others are health Data Subscription Services.
Who are Liom's main competitors?
Broad incumbents on record are Apple, Medtronic Diabetes, Dexcom and Abbott Diabetes Care (Freestyle Libre). Direct peers are Know Labs and Senseonics (Eversense). Emerging players are Ultrahuman, Movano Health and Biolinq. Levels Health is listed as an others.
Does Liom have an API?
No public API is recorded for Liom.
What industry is Liom in?
Liom's product category is Wearable Health Monitoring Devices. Its primary akta.pro industry code is CRACAQAE, Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers), with a secondary code of CRACAIAF, Health Monitoring Wearables (ECG, BP, SpO2, CGM-compatible). Its NAICS code is 334510 and its SIC code is 3845.